BioDesign_Protein drug design platform
De novo protein drug design, Affinity modulation, Epitope-specific antibody design, Fc engineering.
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Others
- Production method
- Available
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- antibody, innovation, protein, drug design
- Category
- Medicines
Galux Inc.
- Verified Certificate
-
1
Product name | BioDesign_Protein drug design platform | Certification | - |
---|---|---|---|
Category | Medicines | Material | - |
Keyword | antibody , innovation , protein , drug design | Unit Size | - |
Brand name | - | Unit Weigh | - |
origin | South Korea | Stock | 999999 |
Supply type | Available | HS code | - |
Product Information
BioDesign is capable of desinging a protein drug (e.g. antibody, cytokine) against a molecular target of interest.
Currently capable of:
- Affinity modulation through insertion/deletion/substitution of amino acids.
- Affinity modulation in a pH-conditioned manner - Can modulate a protein drug to exclusively interact with its target only in a certain pH level (e.g. acidic condition).
- Fc engineering to elicit select desired effector function of an antibody while suppressing other effector function.
Under development:
- Epitope-specific antibody design.
- Modulating the Fc region of an antibody to function like a Fab region and bind to an antigen. This would allow the design of unconventional bi-specific (one epitope with Fab region and another with Fc region) and even tri-specific antibodies.
Our AI learns the physical principles of protein folding and interaction and we incorporate real-world experimental data into its learning process. This enables the AI to cross-reference its theoretical understanding of physics with emperical data allowing it to generate an accurate picture or representation of the protein structure and interection.
B2B Trade
Price (FOB) | Negotiable | transportation | Negotiation Other |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | Others | Shipping time | Negotiable |
- President
- Product Category
- Medicines,Other Pharmaceuticals
- Year Established
- 2020
- Main Markets
-
France
Germany
Japan
U. Kingdom
U.S.A
- Main Product
Related Products
NOVA PMC
Medicine for dentin hypersensitivity
CAR-M1 Macrophage
Lactomin
Novel small molecules for treating NASH